
|Videos|November 29, 2022
Episode 11A: Effect of Trilaciclib in Patients Receiving Chemotherapy for ES-SCLC Treatment
Author(s)Paul A. Bunn, MD
Dr Paul Bunn briefly reviews key efficacy data from a pooled analyses of trilaciclib in chemotherapy induced myelosuppression and discusses strategies to manage neutropenia in patients receiving chemotherapy for extensive-stage small cell lung cancer (ES-SCLC).
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Advanced Renal Cell Carcinoma: Summarizing a Practical First-Line Treatment Algorithm
2
On-Body Injector Technology Streamlines Subcutaneous Myeloma Therapy
3
Allostatic Load: The Role of Chronic Stress in Predicting Early-Onset Cancer Risk
4
Exploring Psilocybin-Assisted Therapy for Cancer Patients' Trauma
5










































